Olliver L.
- Country
- France
- Department
- Hématologie et Thérapie Cellulaire
Research Overview
- An ALFA 2101 multicenter randomized phase II study: CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics
- Phase I/II Evaluation of NMS-03592088, a FLT3, KIT, and CSF1R Inhibitor, in Relapsed/Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
- Phase 3 Study of Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid in Acute Myeloid Leukemia Patients Aged 18-60
Data & Insights
Has run more than one trial at 47 of 82 partner sites.
Specializations
Myeloid Malignancies
This investigator specializes in treating various forms of acute myeloid leukemia (AML), with particular focus on novel therapeutic approaches for both newly diagnosed and relapsed/refractory cases. Their expertise extends to myelodysplastic syndrome (MDS) with specific genetic mutations.
- IDH2-mutated myelodysplastic syndrome
- FLT3-targeted therapies in AML
- High-risk AML treatment strategies
Chronic Leukemias
The investigator has significant experience in managing chronic myeloid disorders, including innovative treatment approaches for various phases of disease progression. Their work encompasses both traditional and emerging therapies.
- Chronic Myelogenous Leukemia in Chronic Phase
- Chronic Myelomonocytic Leukemia
- Tyrosine Kinase Inhibitor therapy
Hematologic Disorders
Their research portfolio includes treatment of essential thrombocythemia and other myeloproliferative conditions, with particular attention to patients who have shown resistance to conventional therapies.
- CD123-positive hematologic malignancies
- Novel therapeutic compounds
- Treatment-resistant blood disorders
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.